Butanedioic acid, 2,3-bis[(4-methylbenzoyl)oxy]-, (2R,3R)-, compd. with(3R,4R)-N,4-dimethyl-1-(phenylmethyl)-3-piperidinamine (1:2),CAS 登记号 540737-29-9,由济南圣和化工有限公司现货供应,可提供纯度 按批次COA提供(不公开发布) 的规格,下游主要用于Organic Chemicals。支持样品与小批量试用,批量价格请联系我们获取,验收以批次 COA 为准。
Organic Chemicals
每批随货提供 COA;可按需提供 MSDS 及技术文件。邮件注明产品名称与 CAS 号,一个工作日内回复报价。
本页已列出 Butanedioic acid, 2,3-bis[(4-methylbenzoyl)oxy]-, (2R,3R)-, compd. with(3R,4R)-N,4-dimethyl-1-(phenylmethyl)-3-piperidinamine (1:2) 的 CAS 号:540737-29-9,可与随货 COA 核对。
常见纯度为 按批次COA提供(不公开发布),包装形式为 按订单/批次确认(不公开发布),特殊规格可在询价时说明。
主要涉及Organic Chemicals。
来信 info@591daili.com 或 WhatsApp 联系,提供产品名称、CAS 号与数量,确认价格与交期后即可安排发货,验收以批次 COA 为准。
Butanedioic acid, 2,3-bis[(4-methylbenzoyl)oxy]-, (2R,3R)-, compd. with(3R,4R)-N,4-dimethyl-1-(phenylmethyl)-3-piperidinamine (1:2) · CAS 540737-29-9 · C22H28N6O8. UNII O1FF4DIV0D.
| CAS Registry Number | 540737-29-9 |
|---|---|
| PubChem CID | 10174505 |
| Molecular formula | C22H28N6O8 |
| IUPAC name | 2-hydroxypropane-1,2,3-tricarboxylic acid;3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile |
| UNII (FDA) | O1FF4DIV0D |
| Molecular Weight | 504.5 |
|---|---|
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 12 |
| Rotatable Bond Count | 8 |
| Exact Mass | 504.19686187 |
| Monoisotopic Mass | 504.19686187 |
| Topological Polar Surface Area | 221 |
| Heavy Atom Count | 36 |
| Formal Charge | 0 |
| Complexity | 716 |
| Reported hazard statements | H302 (97%), H360 (90.9%) |
|---|
H302 (97%): Harmful if swallowed [Warning Acute toxicity, oral]
H360 (90.9%): May damage fertility or the unborn child [Danger Reproductive toxicity]
Tofacitinib citrate; 540737-29-9; Tasocitinib citrate; Xeljanz; CP-690550 citrate; Xeljanz Xr; Tasocitinib monocitrate; CP-690550-10; CP-690,550-10; O1FF4DIV0D; Tofacitinib monocitrate; CHEBI:71197; DTXSID80202404; RefChem:56139; DTXCID40124895; Tofacitinib (CP-690550) Citrate
CAS 540737-29-9; molecular formula C22H28N6O8; molecular weight — g/mol.
Tofacitinib citrate, 540737-29-9, Tasocitinib citrate, Xeljanz, CP-690550 citrate, Xeljanz Xr.
Hazard statements reported: H302, H360.
Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.